HER2 molecular subtype is a dominant subtype of mammary Paget's cells. An immunohistochemical study

Histopathology

Volumn 57, Issue 4, 2010, Pages 564-571

  Sek, Piotr ^a   Zawrocki, Antoni ^b   Biernat, Wojciech ^a,b   Piekarski, Janusz H ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

CK5 6; HER2; Mammary Paget's disease; Molecular subtype; Tissue microarrays

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

ARTICLE; BREAST CARCINOMA; BREAST CELL; CANCER CELL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PAGET NIPPLE DISEASE; PHENOTYPE; PRIORITY JOURNAL; TISSUE MICROARRAY;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; PAGET'S DISEASE, MAMMARY; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TISSUE ARRAY ANALYSIS;

EID: 78650232316     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03665.x     Document Type: Article

References (41)

1. Perou CM, Sorcie T, Eisen MB et al. Molecular portraits of human breast tumors. Nature 2000; 406; 747-752.
2. Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implication. Proc. Natl Acad. Sci. USA 2001; 98; 10869-10874.
3. Sørlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 2003; 100; 8418-8423.
4. Van De Vijver MJ, He YD, Van't Veer LJ et al. A gene expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 2002; 347; 1999-2009.
5. Huang E, Cheng SH, Dressman H et al. Gene expression predictors of breast cancer outcomes. Lancet 2003; 361; 1590-1596.
6. Sortiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population based study. Proc. Natl Acad. Sci. USA 2003; 100; 10393-10398.
7. Livasy CA, Perou CM, Karaca G et al. Identification of a basal-like subtype of breast carcinoma in situ. Hum. Pathol. 2007; 38; 197-204.
8. Bryan BB, Schnitt SJ, Collins LC. Ductal carcinoma in situ with a basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod. Pathol. 2006; 19; 617-621.
9. Tamimi RM, Baer HJ, Marotti J et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res. 2008; 10; R67.
10. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004; 10; 5367-5374.
11. Paget J. On the disease of the mammary areola preceding cancer of the mammary gland. St. Bartholomew Hosp. Rep. 1874; 10; 87-89.
12. Stomper P, Penetrante R, Carson W. Sensitivity of mammography on patients with Paget's disease of the nipple. Breast Dis. 1995; 8; 173-178.
13. Kothari AS, Beechey-Newman N, Hamed H et al. Paget disease of the nipple: a multifocal manifestation of higher-risk disease. Cancer 2002; 95; 1-7.
14. Sheen-Chen SM, Chen HS, Chen WJ, Eng HL, Sheen CW, Chou FF. Paget disease of the breast - an easily overlooked disease? J. Surg. Oncol. 2001; 76; 261-265.
15. Sakorafas GH, Blanchard K, Sarr MG, Farley DR. Paget's disease of the breast. Cancer Treat. Rev. 2001; 27; 9-18.
16. Kollmorgen DR, Varanasi JS, Edge SB, Carson WE III. Paget's disease of the breast: a 33-year experience. J. Am. Coll. Surg. 1998; 187; 171-177.
17. Dixon AR, Galea MH, Ellis IO, Elston CW, Blamey RW. Paget's disease of the nipple. Br. J. Surg. 1991; 78; 722-723.
18. Ashikari R, Park K, Huvos AG, Urban JA. Paget's disease of the breast. Cancer 1970; 2; 680-685.
19. Nance FC, DeLoach DH, Welsh RA, Becker WF. Paget's disease of the breast. Ann. Surg. 1970; 171; 864-872.
20. Chaudary MA, Millis RR, Lane EB, Miller NA. Paget's disease of the nipple: a ten year review including clinical, pathological and immunohistochemical findings. Breast Cancer Res. Treat. 1986; 8; 139-146.
21. Paone J, Baker R. Pathogenesis and treatment of Paget's disease of the breast. Cancer 1981; 48; 825-829.
22. Mai KT. Morphological evidence for field effect as mechanism of tumour spread in mammary Paget disease. Histopathology 1999; 35; 567-576.
23. Mai KT, Yazdi HM, Perkins DG. Mammary Paget's disease: evidence of diverse origin of the disease with subgroup of Paget's disease developing from the superficial portion of lactiferous duct and a discontinuous pattern of tumor spread. Pathol. Int. 1999; 49; 956-961.
24. Jamali FR, Ricci A Jr, Deckers PJ. Paget disease of the nipple-areola complex. Surg. Clin. North Am. 1996; 76; 365-381.
25. Lloyd J, Flanagan AM. Mammary and extramammary Paget's disease. J. Clin. Pathol. 2000; 53; 742-749.
26. Lester T, Wang J, Bourne P, Yang Q, Fu L, Tang P. Different panels of markers should be used to predict mammary Paget's disease associated with in situ or invasive ductal carcinoma of the breast. Ann. Clin. Lab. Sci. 2009; 39; 17-24.
27. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19; 403-410.
28. Morandi L, Pession A, Marucci GL et al. Intraepidermal cells of Paget's carcinoma of the breast can be genetically different from those of the underlying carcinoma. Hum. Pathol. 2003; 34; 1321-1330.
29. Brummer O, Steger HE, Böhmer G, Kühnle H, Perty HU. HER-2/neu expression in Paget disease of the vulva and the female breast. Gynecol. Oncol. 2004; 95; 336-340.
30. Anderson JM, Ariga R, Govil H et al. Assessment of HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in mammary Paget disease and underlying carcinoma. Appl. Immunohistochem. Mol. Morphol. 2003; 11; 120-124.
31. Schelfhout VRJ, Coene ED, Delaey B, Thys S, Page DL, De Potter CR. Pathogenesis of Paget's disease: epidermal heregulin-α, motility factor, and the HER receptor family. J. Natl Cancer Inst. 2000; 92; 622-628.
32. Fu W, Lobocki CA, Silberberg BK, Chelladurai M, Young SC. Molecular markers in Paget disease of the breast. J. Surg. Oncol. 2001; 77; 171-178.
33. Liegl B, Horn LC, Moinfar F. Androgen receptors are frequently expressed in mammary and extramammary Paget's disease. Mod. Pathol. 2005; 18; 1283-1288.
34. Ginestier C, Charafe-Jauffret E, Bertucci F et al. Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. Am. J. Pathol. 2002; 161; 1223-1233.
35. Bucher C, Torhorst J, Bubendorf L et al. Tissue microarrays ('tissue chips') for high-throughput cancer genetics: linking of molecular changes to clinical endpoints. Am. J. Hum. Genet. 1999; 65(Suppl.); 43 [Abstract].
36. Gillett CE, Springall RJ, Barnes DM, Hanby AM. Multiple tissue core arrays in histopathology research: a validation study. J. Pathol. 2000; 192; 549-553.
37. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab. Invest. 2000; 80; 1943-1949.
38. Zhang D, Salto-Tellez M, Putti TC, Do E, Koay ES. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod. Pathol. 2003; 16; 79-84.
39. Hoos A, Cordon-Cardo C. Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab. Invest. 2001; 81; 1331-1338.
40. Nocito A, Kononen J, Kallioniemi OP, Sauter G. Tissue microarrays (TMAs) for high-throughput molecular pathology research. Int. J. Cancer 2001; 94; 1-5.
41. Kallioniemi OP, Wagner U, Kononen J, Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum. Mol. Genet. 2001; 10; 657-662.